Header Logo

Connection

VINCENT TAM to Polymyxin B

Back to Details
This is a "connection" page, showing publications VINCENT TAM has written about Polymyxin B.
VINCENT TAM
Connection Strength
10.618
Polymyxin B
  1. Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury. Am J Physiol Renal Physiol. 2024 Jul 01; 327(1):F137-F145.
    View in: PubMed
    Score: 0.875
  2. Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 09; 104(3):534-538.
    View in: PubMed
    Score: 0.562
  3. Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 11; 61(11).
    View in: PubMed
    Score: 0.554
  4. Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 04; 61(4).
    View in: PubMed
    Score: 0.532
  5. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 01; 61(1).
    View in: PubMed
    Score: 0.524
  6. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 11; 60(11):6980-6982.
    View in: PubMed
    Score: 0.517
  7. Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrob Agents Chemother. 2016 Feb; 60(2):1029-34.
    View in: PubMed
    Score: 0.487
  8. Analytical and functional determination of polymyxin B protein binding in serum. Antimicrob Agents Chemother. 2015 Nov; 59(11):7121-3.
    View in: PubMed
    Score: 0.478
  9. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5.
    View in: PubMed
    Score: 0.461
  10. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015; 70(6):1903-7.
    View in: PubMed
    Score: 0.459
  11. Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?". Antimicrob Agents Chemother. 2014 Oct; 58(10):6339.
    View in: PubMed
    Score: 0.448
  12. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother. 2014 Jul; 58(7):4200-2.
    View in: PubMed
    Score: 0.434
  13. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013 Dec; 42(6):559-64.
    View in: PubMed
    Score: 0.415
  14. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother. 2013 May; 68(5):1104-10.
    View in: PubMed
    Score: 0.399
  15. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012 Sep; 56(9):4625-9.
    View in: PubMed
    Score: 0.382
  16. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother. 2011 Sep; 55(9):4490-1.
    View in: PubMed
    Score: 0.358
  17. Pharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia. Pediatr Infect Dis J. 2011 Jun; 30(6):537-9.
    View in: PubMed
    Score: 0.356
  18. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 2011 May; 52(10):1280-1.
    View in: PubMed
    Score: 0.354
  19. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 degrees C. Am J Health Syst Pharm. 2010 Jul 15; 67(14):1191-4.
    View in: PubMed
    Score: 0.335
  20. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents. 2010 Mar; 35(3):308-10.
    View in: PubMed
    Score: 0.323
  21. Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother. 2009 Mar; 63(3):627-8; author reply 628-9.
    View in: PubMed
    Score: 0.299
  22. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs. 2008 May; 17(5):661-8.
    View in: PubMed
    Score: 0.287
  23. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Sep; 49(9):3624-30.
    View in: PubMed
    Score: 0.239
  24. Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023 10 03; 78(10):2435-2441.
    View in: PubMed
    Score: 0.209
  25. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 01; 39(1):10-39.
    View in: PubMed
    Score: 0.150
  26. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34.
    View in: PubMed
    Score: 0.113
  27. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct; 5(5):811-21.
    View in: PubMed
    Score: 0.069
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.